Timely diagnosis and prompt treatment initiation are essential for improving outcomes in patients with acquired thrombotic thrombocytopenic purpura (aTTP/iTTP). In this session, we will examine the latest real-world evidence of early treatment initiation with CABLIVI, how early therapeutic strategies influence patient outcomes, the latest updated international treatment guidelines, and highlight healthcare resource utilization data. Attendees will gain practical strategies to optimize treatment timing and enhance care for patients with aTTP/iTTP.